Literature DB >> 26214357

Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.

Jing Zhao1, Si-Shen Feng2,3.   

Abstract

A major problem in cancer treatment is the multidrug resistance. siRNA inhibitors have great advantages to solve the problem, if the bottleneck of their delivery could be well addressed by the various nanocarriers. Moreover, co-delivery of siRNA together with the various anticancer agents in one nanocarrier may maximize their additive or synergistic effect. This review provides a comprehensive summary on the state-of-the-art of the nanocarriers, which may include prodrugs, micelles, liposomes, dendrimers, nanohydrogels, solid lipid nanoparticles, nanoparticles of biodegradable polymers and nucleic acid nanocarriers for delivery of siRNA and co-delivery of siRNA together with anticancer agents with focus on synthesis of the nanocarrier materials, design and characterization, in vitro and in vivo evaluation, and prospect and challenges of nanocarriers.

Entities:  

Keywords:  RNAi therapeutics; biodegradable polymer; cancer nanotechnology; chemotherapy; molecular biomaterials; multidrug resistance; nanotheranostics

Mesh:

Substances:

Year:  2015        PMID: 26214357     DOI: 10.2217/nnm.15.61

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  13 in total

Review 1.  Capacity of gold nanoparticles in cancer radiotherapy.

Authors:  Nadeem M S Nagi; Yasir A M Khair; Ahmed M E Abdalla
Journal:  Jpn J Radiol       Date:  2017-08-09       Impact factor: 2.374

Review 2.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

Review 3.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

Review 4.  Application of nanotechnology to cancer radiotherapy.

Authors:  Yu Mi; Zhiying Shao; Johnny Vang; Orit Kaidar-Person; Andrew Z Wang
Journal:  Cancer Nanotechnol       Date:  2016-12-19

Review 5.  Nano-based delivery of RNAi in cancer therapy.

Authors:  Yong Xin; Min Huang; Wen Wen Guo; Qian Huang; Long Zhen Zhang; Guan Jiang
Journal:  Mol Cancer       Date:  2017-07-28       Impact factor: 27.401

6.  Acid-degradable Dextran as an Image Guided siRNA Carrier for COX-2 Downregulation.

Authors:  Zhihang Chen; Balaji Krishnamachary; Marie-France Penet; Zaver M Bhujwalla
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

7.  Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors.

Authors:  Willi Jugel; Achim Aigner; Susanne Michen; Alexander Hagstotz; Alexander Ewe; Dietmar Appelhans; Gabriele Schackert; Achim Temme; Stefanie Tietze
Journal:  Pharmaceutics       Date:  2021-05-08       Impact factor: 6.321

Review 8.  The potential of antisense oligonucleotide therapies for inherited childhood lung diseases.

Authors:  Kelly M Martinovich; Nicole C Shaw; Anthony Kicic; André Schultz; Sue Fletcher; Steve D Wilton; Stephen M Stick
Journal:  Mol Cell Pediatr       Date:  2018-02-06

9.  Conjugation of Doxorubicin to siRNA Through Disulfide-based Self-immolative Linkers.

Authors:  Florian Gauthier; Jean-Rémi Bertrand; Jean-Jacques Vasseur; Christelle Dupouy; Françoise Debart
Journal:  Molecules       Date:  2020-06-11       Impact factor: 4.411

Review 10.  The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.

Authors:  Simoneide S Titze-de-Almeida; Cristina Soto-Sánchez; Eduardo Fernandez; James B Koprich; Jonathan M Brotchie; Ricardo Titze-de-Almeida
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.